Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
10
06
2019
accepted:
10
12
2019
revised:
26
11
2019
pubmed:
4
1
2020
medline:
22
6
2021
entrez:
4
1
2020
Statut:
ppublish
Résumé
Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for several hematologic malignancies, such as multiple myeloma, and lymphomas. ASCT typically involves support with blood product transfusion. Thus, difficulties arise when Jehovah's Witness patients refuse blood transfusions. In order to demonstrate the safety of performing "bloodless" ASCT (BL-ASCT), we performed a retrospective analysis of 66 Jehovah's Witnesses patients who underwent BL-ASCT and 1114 non-Jehovah's Witness patients who underwent transfusion-supported ASCT (TF-ASCT) at Cedars-Sinai Medical Center between January 2000 and September 2018. Survival was compared between the two groups. Transplant-related complications, mortality, engraftment time, length of hospital stay, and number of ICU transfers were characterized for the BL-ASCT group. One year survival was found to be 87.9% for both groups (P = 0.92). In the BL-ASCT group, there was one death prior to the 30 days post transplant due to CNS hemorrhage, and one death prior to 100 days due to sepsis. Based on our data, BL-ASCT can be safely performed with appropriate supportive measures, and we encourage community oncologists to promptly refer JW patients for transplant evaluation when ASCT is indicated.
Identifiants
pubmed: 31898692
doi: 10.1038/s41409-019-0777-9
pii: 10.1038/s41409-019-0777-9
pmc: PMC7269908
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1059-1067Références
National Comprehensive Cancer Network Guidelines in Oncology. B Cell Lymphomas (version 2.2018). 2019. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf . Accessed 13 Nov 2019.
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Moreau P. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl J Med. 2017;376:1311–20.
doi: 10.1056/NEJMoa1611750
Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131–6.
doi: 10.1182/blood.V92.9.3131
Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, et al. Durable remission with salvage second auto transplants in patients with multiple myeloma. Cancer. 2012;118:3549–55.
doi: 10.1002/cncr.26662
Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Reece DE, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18:773–9.
doi: 10.1016/j.bbmt.2011.10.044
Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Clin Oncol. 2010;28:4184–90.
doi: 10.1200/JCO.2010.28.1618
Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, et al. Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer. 2019;125:185–93.
doi: 10.1002/cncr.31677
Khan R, Mott SL, Schultz A, Jethava YS, Tricot G. Bloodless tandem autologous transplant in Jehovah's Witness patients. Bone Marrow Transpl. 2018;53:1428–33.
doi: 10.1038/s41409-018-0132-6
Bolwell BJ, Goormastic M, Andresen S, Overoyer B, Pohlman B, Kalaycio M. Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count. Bone Marrow Transpl. 1997;20:459–63.
doi: 10.1038/sj.bmt.1700920
Coltoff A, Shreenivas A, Afshar S, Steinberg A. A single-institution experience of performing bloodless transplant in Jehovah’s Witness patients. Hematol Oncol Stem Cell Ther. 2019;12:44–9.
doi: 10.1016/j.hemonc.2018.11.003
Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. Br Med J. 2001;322:37–9.
doi: 10.1136/bmj.322.7277.37
Lee E. Why some Jehovah’s Witnesses accept blood and conscientiously reject official Watchtower Society blood policy. J Med Ethics. 2000;26:375–80.
doi: 10.1136/jme.26.5.375
Ford PA, Grant SJ, Mick R, Keck G. Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. J Clin Oncol. 2015;33:1674–9.
doi: 10.1200/JCO.2014.57.9912
Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol. 2004;22:4087–94.
doi: 10.1200/JCO.2004.01.144
Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460–8.
doi: 10.1200/JCO.2004.10.054
Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1233–7.
doi: 10.1016/j.bbmt.2013.05.019
Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transpl. 2006;37:387–92.
doi: 10.1038/sj.bmt.1705246
Stanworth SJ, Estcourt LJ, Powter G, Kahan B, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N. Engl J Med. 2013;368:1771–80.
doi: 10.1056/NEJMoa1212772
American Society of Clinical Oncology. ASCO Guidelines [Internet]. American Society of Clinical Oncology. 2017. Available from: https://www.asco.org/sites/new-www.asco.org/files/content-files/2017-platelet-transfusion-slides.pdf . Accessed 13 Nov 2019.
Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, et al. Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. Br J Haematol. 2013;5:738–4020.
doi: 10.1111/bjh.12284
Moradi S, Jahanian-Najafabadi A, Roudkenar MH. Artificial blood substitutes: first steps on the long route to clinical utility. Clin Med Insights Blood Disord. 2016;9:33–41.
doi: 10.4137/CMBD.S38461
Bari S, Rabinovich M, Curry M, Jain SR, Cafuir L. Use of hemoglobin based oxygen carrier HBOC-021 (Hemopure) as a bridge during emergencies in patients unable to receive blood products: experience at a tertiary care center. Blood. 2017;130(Suppl 1):4926.
Posluszny JA, Napolitano LM. Hemoglobin-based oxygen carrier for traumatic hemorrhagic shock treatment in a Jehovah's Witness. Arch Trauma Res. 2016;5:e30610.
pubmed: 27679789
pmcid: 5035516
Pew Research Center. Religious Landscape Study [Internet]. Lipka M. A closer look at Jehovah’s Witnesses living in the U.S. April 26, 2016. Available from: https://www.pewresearch.org/fact-tank/2016/04/26/a-closer-look-at-jehovahs-witnesses-living-in-the-u-s/ . Accessed 13 Nov 2019.